期刊文献+

扶正清肺汤对艾滋病合并肺部感染患者PCT、CRP及CD4^+水平的影响 被引量:6

Effect of Fuzheng Qingfei Decoction on PCT,CRP and CD4^+ Levels in Patients with AIDS Complicated with Pulmonary Infection
下载PDF
导出
摘要 目的探讨扶正清肺汤对艾滋病合并肺部感染患者PCT、CRP及CD4+水平的影响。方法选取收治的102例艾滋病合并肺部感染患者作为观察对象,按给药方案不同分为研究组和对照组,对照组患者给予一线抗病毒药物治疗,并根据肺部感染情况给予抗感染治疗,研究组患者在对照组基础上加服扶正清肺汤,对2组患者治疗后的临床体征疗效及不同时间段的PCT、CRP及CD4+水平及不良反应情况进行分析。结果研究组患者的临床体征治疗总有效率高于对照组患者,差异显著(P=0.038)。治疗前2组患者的PCT、CRP及CD4+水平比较无显著差异;同组患者治疗前后的PCT、CRP及CD4+水平比较均有统计学差异(P>0.05);治疗后2组患者PCT、CRP水平均有所降低,研究组降低更为显著(P<0.05);治疗后2组患者CD4+水平比较,研究组升高情况略优于对照组。2组患者均未发生严重药物不良反应事件。结论对于艾滋病合并肺部感染患者采用扶正清肺汤行辅助治疗,可显著改善PCT、CRP及CD4+水平,可改善机体免疫力,抑制炎症因子释放。 Objective To investigate the effect of Fuzheng Qingfei decoction on PCT,CRP and CD4+levels in patients with AIDS complicated with pulmonary infection.Methods 102 patients with AIDS complicated with pulmonary infection were divided into study group and control group according to the different administration scheme.The curative effect of clinical signs,the level of PCT,CRP and CD4+and the adverse reactions in different time periods of the two groups were analyzed.Results The total effective rate of clinical signs in the study group was higher than that in the control group(90.20%vs 74.51%),and the difference was significant(P=0.038).There was no significant difference in the levels of PCT,CRP and CD4 in each group before and after treatment,but there was significant difference in the levels of PCT,CRP and CD4 in the same group before and after treatment,and the levels of PCT,CRP in the two groups were decreased after treatment,especially in the study group(P<0.05).The level of CD4 in the study group was slightly higher than that in the control group after treatment.No serious adverse drug reactions occurred.Conclusion Fuzheng Qingfei decoction can significantly improve PCT,CRP and CD4+in patients with AIDS complicated with pulmonary infection.It can improve the immunity and inhibit the release of inflammatory factors.
作者 王延丽 赵清霞 刘旭辉 侯明杰 原海珍 WANG Yanli;ZHAO Qingxia;LIU Xuhui;HOU Mingjie;YUAN Haizhen(Department of Infectious Disease,Zhengzhou Sixth People’s Hospital,Henan Province,Zhengzhou 450002,China)
出处 《光明中医》 2020年第1期11-13,共3页 GUANGMING JOURNAL OF CHINESE MEDICINE
关键词 艾滋病 扶正清肺汤 肺部感染 PCT 中医药疗法 AIDS Fuzheng Qingfei decoction pulmonary infection PCT therapy of TCM
  • 相关文献

参考文献6

二级参考文献60

  • 1Sherman KE, Terrault N, Barin B, Rouster SD, Shata MT; HIV-TR Investigators. Hepatitis E infection in HIV- infected liver and kidney transplant candidates [J]. J Viral Hepat, 2014, 21(8).. e74-e77.
  • 2Kuniholm MH, Ong E, Hogema BM, Koppelman M, Anastos K, Peters MG, Seaberg EC, Chen Y, Nelson KE, Linnen JM. Acute and chronic hepatitis E virus infection in HIV-infected U.S. women [J]. Hepatology, 2016, 63(3): 712-720.
  • 3Geng Y, Zhao C, Huang W, Harrison TJ, Zhang H, Geng K, Wang Y. Detection and assessment of infectivity of hepatitis E virus in urine [J]. J Hepatol, 2016, 64(1): 37-43.
  • 4Geng , Zhang H, Huang W, Harrison TJ, Geng K, Li Z, Wang Y. Persistent hepatitis E virus genotype 4 infection in a child with acute lymphoblastic leukemia E J/OLd. Hepat Mon, 2014. http://www, ncbi. nlm. nih. gov/pmc/ articles/PMC3929864.
  • 5Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection in immunosuppressed patients: natural history and therapy [J]- Semin Liver Dis, 2013, 33(1): 62-70.
  • 6Cleland A, Smith L, Crossan C, Blatchford O, Dalton HR, Scobie L, Petrik J. Hepatitis E virus in Scottish blood donors [J]. Vox Sang, 2013, 105(4).. 283-289.
  • 7Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC, Xia NS. Long-term efficacy of a hepatitis E vaccine [J]. N Engl J Med, 2015, 372(10) .. 914- 922.
  • 8Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults, a large-scale, randomised, double-blind placebo- controlled, phase 3 trial [J]. Lancet, 2010, 376 (9744) 895-902.
  • 9Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity [J]. Rev Med Virol, 2012, 22 (5): 339-349.
  • 10WHO. Hepatitis E vaccine: WHO position paper, May 2015 [J]. Wkly Epidemiol Rec, 2015, 90(18): 185-200.

共引文献325

同被引文献83

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部